Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
about
Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaSecond-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of lifeCritical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature reviewEfficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trialsComparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyProfile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a reviewLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsEffective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database studyLong-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialRecent advances in understanding schizophreniaSchizophrenia: overview and treatment options.Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaImpact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophreniaPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsCognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisEffectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoateEffectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate.Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability.Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisPaliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional studySwitching away from pipotiazine palmitate: a naturalistic study.Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.Glutamatergic agents for schizophrenia: current evidence and perspectives.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline.Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.
P2860
Q26745792-64450011-9D8F-4554-9AF2-C8589FB4E7C0Q26752965-E75A738F-841B-4532-931C-312A6D2B863CQ26774421-5FA853EF-7F86-4399-9176-3A7FCF0E149BQ26781173-61678F76-6C30-4683-BC77-FD828F27851AQ27320151-08BE4F09-E078-4EDC-A930-36BD604B44C6Q28084899-8394A59E-E817-4E2E-84F0-F7FF922A9C4AQ28085407-4F04F487-957F-4E6D-A875-EEFB5B11433DQ30276915-5F9BBE3D-C19E-4152-9B19-659083446307Q30382281-BEB4F947-821F-44DD-B881-6D4C42CC6688Q33614458-89CD233A-88AB-4F82-BA42-35986D506B36Q33650097-60179632-9891-4BB4-B1BC-AF43F8E6EE13Q33797431-00ABE0BA-FD65-4837-9FC4-0E84CC2F3D38Q33802918-C650E3F0-0B28-40AB-98AA-212D7D08BC7EQ33914295-566875BC-2723-4E24-ADD6-5A4F20F573C2Q33942094-BCE63875-1E00-489A-A987-2F70D92F2C6CQ34154951-E39AE61A-29D8-436C-BBE7-C4297B68E124Q34436401-7FA1B489-BF7A-4562-84D6-A49F7DE895F0Q34501911-640BE6D2-3420-4FBF-95F1-28257D184320Q35186007-A87C9806-3670-468D-AE7A-CD0F97DC5046Q35566090-34998296-6704-4FF0-8786-92A12E0417D0Q35882300-C82331A6-E2F1-453C-8473-6B32F0D5488BQ36001512-A95BFDA2-951B-4236-A4C4-66A731602EC8Q36033253-7883959C-A0AC-4F61-8C89-32A9D69F41C4Q36550998-01237E6A-D3F0-49C4-A45E-EBD990B8E0F5Q36568895-8735864C-9E18-4561-9E08-0384C76A5E14Q36816768-AE33C1CA-977C-4D72-8F3D-D8FAC6066243Q36981526-C8ACD3CA-C8B5-4929-9D6A-FDC76B21878DQ37011447-C7F5B2A2-A8D4-4A07-A7A5-296FE7574DD4Q37280123-4126DC1A-7D1D-4EEC-9FD5-7AD51643313BQ37299914-7752CB48-9153-4A57-8A38-26A7A65153B6Q37547469-C0171580-E523-41F1-881F-CC9E38A2D96AQ37582712-02B394E9-CC59-454D-AEF5-3FA4D8197574Q37722508-491021EF-DB26-4729-B39C-7881C89FEB13Q37735342-9949A48B-0CF7-4B70-9364-81D615594662Q38206231-AB2ED211-A8B7-4190-8841-6BDB1835A818Q38233228-CF6FE741-D414-46B5-AE59-8506AEE53360Q38444551-763600F6-847C-4CB6-AB94-AC96ECCD1C3DQ38570636-07E4BEA4-D152-4711-BE66-0C9C070B0FF2Q38578316-7CC2A7A4-447D-4776-AA03-7A9D193B72DDQ38592404-BCFBF0ED-DD5E-4F28-910D-74B7B81FF773
P2860
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-acting injectable versus ...... lysis of mirror-image studies.
@en
type
label
Long-acting injectable versus ...... lysis of mirror-image studies.
@en
prefLabel
Long-acting injectable versus ...... lysis of mirror-image studies.
@en
P2093
P356
P1476
Long-acting injectable versus ...... lysis of mirror-image studies.
@en
P2093
Christoph U Correll
Masahiro Nitta
Michael Borenstein
Taishiro Kishimoto
P304
P356
10.4088/JCP.13R08440
P50
P577
2013-10-01T00:00:00Z